United Therapeutics UTHR Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total revenues by Product | ||||||
| Adcirca | $26.9M-10.3% | $30M+11.5% | $26.9M+11.2% | $24.2M+3.4% | $23.4M-1.7% | |
| Nebulized Tyvaso | $549.1M-6.2% | $585.7M-2.8% | $602.7M-2.8% | $620.1M+2.4% | $605.6M+3.2% | |
| Orenitram | $511.8M+3.0% | $496.9M+2.8% | $483.5M+3.8% | $465.6M+3.7% | $448.8M+3.3% | |
| Remodulin | $515.2M-2.2% | $526.8M-1.2% | $533.3M-0.4% | $535.7M-2.3% | $548.3M+1.9% | |
| Tyvaso DPI | $1.32B+2.2% | $1.29B+5.3% | $1.23B+5.3% | $1.17B+5.1% | $1.11B+7.3% | |
| Unituxin | $222.2M-2.0% | $226.8M-2.2% | $232M-5.4% | $245.2M+2.8% | $238.5M-0.1% | |
| Gross Profit by Product | ||||||
| Adcirca | $15.4M-8.9% | $16.9M+9.7% | $15.4M+10.0% | $14M+5.3% | $13.3M-2.9% | |
| Nebulized Tyvaso | $521.8M-6.6% | $558.5M-2.8% | $574.5M-2.5% | $589.2M+3.0% | $571.9M+3.5% | |
| Orenitram | $484M+3.4% | $468.2M+2.7% | $456M+4.3% | $437.3M+3.8% | $421.3M+3.8% | |
| Remodulin | $463.6M-2.9% | $477.5M-0.3% | $478.7M-0.5% | $480.9M-2.8% | $495M+0.9% | |
| Tyvaso DPI | $1.07B-0.7% | $1.08B+4.3% | $1.04B+4.6% | $991.4M+4.9% | $945.4M+6.8% | |
| Unituxin | $204.9M-2.1% | $209.3M-4.1% | $218.2M-5.2% | $230.2M+3.5% | $222.5M-0.8% | |
| Cost of Sales by Product | ||||||
| Adcirca | $11.5M-12.2% | $13.1M+13.9% | $11.5M+12.7% | $10.2M+1.0% | $10.1M0.0% | |
| Nebulized Tyvaso | $27.3M+0.4% | $27.2M-3.5% | $28.2M-8.7% | $30.9M-8.3% | $33.7M-1.2% | |
| Orenitram | $27.8M-3.1% | $28.7M+4.4% | $27.5M-2.8% | $28.3M+2.9% | $27.5M-3.2% | |
| Remodulin | $51.6M+4.7% | $49.3M-9.7% | $54.6M-0.4% | $54.8M+2.8% | $53.3M+12.4% | |
| Tyvaso DPI | $245.7M+16.7% | $210.6M+10.7% | $190.3M+9.3% | $174.1M+6.7% | $163.2M+10.0% | |
| Unituxin | $17.3M-1.1% | $17.5M+26.8% | $13.8M-8.0% | $15M-6.3% | $16M+11.1% | |
| Total revenues by Geography | ||||||
| ROW | $138.2M-5.1% | $145.7M+5.2% | $138.5M-4.7% | $145.4M-0.6% | $146.3M+6.2% | |
| U.S. | $3.03B-0.2% | $3.04B+1.6% | $2.99B+2.0% | $2.93B+3.0% | $2.85B+3.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does United Therapeutics break its business down?
- United Therapeutics (UTHR) reports total revenues by product across 6 parts — Adcirca, Nebulized Tyvaso, Orenitram, Remodulin and Tyvaso DPI. Each is extracted from the segment footnotes and tracked over time.
- Where does United Therapeutics's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in United Therapeutics's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
